September 20, 2023 11:26 AM EDT
News Briefing

Atara to file T cell im­munother­a­py in the US in 2024; Rayze­Bio clos­es $358M IPO

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Ayisha Sharma

News Reporter

Atara Bio­ther­a­peu­tics said Tues­day that it plans to sub­mit its T cell im­munother­a­py for ap­proval in the US next year. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times